Skip to main content

UTAH MEDICAL PRODUCTS INC

For the period ended Mar 31, 2025. Filed May 15, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

UTMD$72.23+1.7%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Item 1. Financial Statements

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
MARCH 31, 2025 AND DECEMBER 31, 2024
(in thousands)
(unaudited) · (audited)
MARCH 31, 2025 · DECEMBER 31, 2024
ASSETS
Current assets:
Cash & Investments$83,325$82,976
Accounts & other receivables, net3,9444,094
Inventories8,6488,812
Other current assets482448
Total current assets96,39996,330
Property and equipment, net9,9459,763
Goodwill13,77013,580
Other intangible assets54,65053,772
Other intangible assets - accumulated amortization(52,245)(50,907)
Other intangible assets, net2,4052,865
Total assets$122,519$122,538
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$914$696
Accrued expenses3,4103,061
Total current liabilities4,3243,757
Deferred tax liability - Femcare IIA494603
Other long term liabilities--
Long-term lease liability269282
Deferred income taxes385469
Total liabilities5,4725,111
Stockholders' equity:
Common stock - $0.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2025, 3,281 shares and December 31, 2024, 3,335 shares3333
Accumulated other comprehensive loss(11,190)(11,908)
Additional paid-in capital · - · -
Retained earnings128,204129,302
Total stockholders' equity117,047117,427
Total liabilities and stockholders' equity$122,519$122,538
see notes to consolidated condensed financial statements
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.